NeOnc sets Oct 23 closing for $50M partnership with Quazar Investment after UAE approvals

NEONC TECHNOLOGIES HOLDINGS, INC.

Closing of $50M strategic partnership with Quazar Investment by Oct 23 after UAE tax/regulatory approvals.
$15M of funds allocated for Phase 2B clinical trials and infrastructure in UAE and MENA region.
Four upcoming clinical trials: NEO100-01, NEO100-02, NEO212 (Phase 2a/2b), and NEO100-03 (Phase 1 pediatric).
NuroMENA Holdings, the Abu Dhabi-based operating subsidiary, incorporated on August 6, 2025.
Quazar Investment has over $3.3B in AUM; partnership involves significant equity investment in NeOnc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.